留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

2020年第3季度肾移植领域最新文献解读

马茂林 石炳毅 孙启全

马茂林, 石炳毅, 孙启全. 2020年第3季度肾移植领域最新文献解读[J]. 器官移植, 2021, 12(1): 37-42. doi: 10.3969/j.issn.1674-7445.2021.01.006
引用本文: 马茂林, 石炳毅, 孙启全. 2020年第3季度肾移植领域最新文献解读[J]. 器官移植, 2021, 12(1): 37-42. doi: 10.3969/j.issn.1674-7445.2021.01.006
Ma Maolin, Shi Bingyi, Sun Qiquan. Interpretation of latest literatures on renal transplantation in the third quarter of 2020[J]. ORGAN TRANSPLANTATION, 2021, 12(1): 37-42. doi: 10.3969/j.issn.1674-7445.2021.01.006
Citation: Ma Maolin, Shi Bingyi, Sun Qiquan. Interpretation of latest literatures on renal transplantation in the third quarter of 2020[J]. ORGAN TRANSPLANTATION, 2021, 12(1): 37-42. doi: 10.3969/j.issn.1674-7445.2021.01.006

2020年第3季度肾移植领域最新文献解读

doi: 10.3969/j.issn.1674-7445.2021.01.006
基金项目: 

国家自然科学基金 81770753

国家自然科学基金 81970650

国家重点研发计划课题 2018YFA0108804

详细信息
    通讯作者:

    孙启全,男,1973年生,博士,教授,研究方向为器官移植临床与基础免疫学,Email: sunqiq@mail.sysu.edu.cn

  • 中图分类号: R617, R392.4, R63

Interpretation of latest literatures on renal transplantation in the third quarter of 2020

More Information
  • 摘要: 如何改善移植肾的长期预后和解决供肾短缺仍是困扰临床医师的两大难题,其中缺血-再灌注损伤(IRI)、排斥反应、感染、免疫抑制治疗是肾移植研究领域的重要问题。因此,加强肾移植领域文献学习,了解移植肾相关疾病的本质及国际前沿研究热点,有助于临床进一步改善移植肾功能和延长移植肾的存活时间。本文就2020年第3季度肾移植领域的研究热点、最新进展并结合第12期岭南读书会的会议纪要作一文献解读,并从IRI、排斥反应和感染3个方面进行综述。

     

  • [1] SALVADORI M, ROSSO G, BERTONI E. Update on ischemia-reperfusion injury in kidney transplantation: pathogenesis and treatment[J]. World J Transplant, 2015, 5(2):52-67. DOI: 10.5500/wjt.v5.i2.52.
    [2] PERICO N, CATTANEO D, SAYEGH MH, et al. Delayed graft function in kidney transplantation[J]. Lancet, 2004, 364(9447):1814-1827. DOI: 10.1016/S0140-6736(04)17406-0.
    [3] LEFER DJ, BOLLI R. Development of an NIH consortium for preclinicAl assESsment of cARdioprotective therapies (CAESAR): a paradigm shift in studies of infarct size limitation[J]. J Cardiovasc Pharmacol Ther, 2011, 16(3/4):332-339. DOI: 10.1177/1074248411414155.
    [4] CAVAILLÉ-COLL M, BALA S, VELIDEDEOGLU E, et al. Summary of FDA workshop on ischemia reperfusion injury in kidney transplantation[J]. Am J Transplant, 2013, 13(5):1134-1148. DOI: 10.1111/ajt.12210.
    [5] LINDEMAN JH, WIJERMARS LG, KOSTIDIS S, et al. Results of an explorative clinical evaluation suggest immediate and persistent post-reperfusion metabolic paralysis drives kidney ischemia reperfusion injury[J]. Kidney Int, 2020, 98(6):1476-1488. DOI:10.1016/j.kint. 2020.07.026.
    [6] FONTANA L, PARTRIDGE L, LONGO VD. Extending healthy life span--from yeast to humans[J]. Science, 2010, 328(5976):321-326. DOI: 10.1126/science.1172539.
    [7] VERMEIJ WP, DOLLÉ ME, REILING E, et al. Restricted diet delays accelerated ageing and genomic stress in DNA-repair-deficient mice[J]. Nature, 2016, 537(7620):427-431. DOI: 10.1038/nature19329.
    [8] JONGBLOED F, DE BRUIN RWF, STEEG HV, et al. Protein and calorie restriction may improve outcomes in living kidney donors and kidney transplant recipients[J]. Aging (Albany NY), 2020, 12(13):12441-12467. DOI: 10.18632/aging.103619.
    [9] THOMPSON ER, BATES L, IBRAHIM IK, et al. Novel delivery of cellular therapy to reduce ischemia reperfusion injury in kidney transplantation[J]. Am J Transplant, 2020, DOI: 10.1111/ajt.16100[Epub ahead of print].
    [10] STEICHEN C, ERPICUM P. Combining cell-based therapy and normothermic machine perfusion for kidney graft conditioning has gone one step further[J]. Am J Transplant, 2020, DOI: 10.1111/ajt.16260[Epub ahead of print].
    [11] JANSEN MPB, PULSKENS WPC, UIL M, et al. Urinary mitochondrial DNA associates with delayed graft function following renal transplantation[J]. Nephrol Dial Transplant, 2020, 35(8):1320-1327. DOI: 10.1093/ndt/gfy372.
    [12] VAN DER ZWAN M, CLAHSEN-VAN GRONINGEN MC, VAN DEN HOOGEN MWF, et al. Comparison of alemtuzumab and anti-thymocyte globulin treatment for acute kidney allograft rejection[J]. Front Immunol, 2020, 11:1332. DOI: 10.3389/fimmu.2020.01332.
    [13] SELLARÉS J, DE FREITAS DG, MENGEL M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence[J]. Am J Transplant, 2012, 12(2):388-399. DOI: 10.1111/j.1600-6143.2011.03840.x.
    [14] JOHNSON RK, SARMARAPUNGAVAN D, PARASURAMAN RK, et al. Acute tubular injury is an important component in type Ⅰ acute antibody-mediated rejection[J]. Transplant Proc, 2013, 45(9):3262-3268. DOI: 10.1016/j.transproceed.2013.05.012.
    [15] CLOTET-FREIXAS S, MCEVOY CM, BATRUCH I, et al. Extracellular matrix injury of kidney allografts in antibody-mediated rejection: a proteomics study[J].J Am Soc Nephrol, 2020, 31(11):2705-2724. DOI: 10.1681/ASN.2020030286.
    [16] WIEBE C, RUSH DN, GIBSON IW, et al. Evidence for the alloimmune basis and prognostic significance of borderline T cell-mediated rejection[J]. Am J Transplant, 2020, 20(9):2499-2508. DOI: 10.1111/ajt.15860.
    [17] SENEV A, COEMANS M, LERUT E, et al. Eplet mismatch load and de novo occurrence of donor-specific anti-HLA antibodies, rejection, and graft failure after kidney transplantation: an observational cohort study[J]. J Am Soc Nephrol, 2020, 31(9):2193-2204. DOI: 10.1681/ASN.2020010019.
    [18] MORATH C, DÖHLER B, KÄLBLE F, et al. Pre-transplant HLA antibodies and delayed graft function in the current era of kidney transplantation[J]. Front Immunol, 2020, 11:1886. DOI: 10.3389/fimmu.2020.01886.
    [19] SHISHIDO S, ASANUMA H, NAKAI H, et al. The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy[J]. J Am Soc Nephrol, 2003, 14(4):1046-1052. DOI: 10.1097/01.asn.0000056189.02819.32.
    [20] KUYPERS DR. Immunosuppressive drug therapy and subclinical acute renal allograft rejection: impact and effect[J]. Transplantation, 2008, 85(7 Suppl):S25-S30. DOI: 10.1097/TP.0b013e318169c48d.
    [21] HEILMAN RL, DEVARAPALLI Y, CHAKKERA HA, et al. Impact of subclinical inflammation on the development of interstitial fibrosis and tubular atrophy in kidney transplant recipients[J]. Am J Transplant, 2010, 10(3):563-570. DOI: 10.1111/j.1600-6143.2009.02966.x.
    [22] NANKIVELL BJ. The meaning of borderline rejection in kidney transplantation[J]. Kidney Int, 2020, 98(2):278-280. DOI: 10.1016/j.kint.2020.04.052.
    [23] O'CONNELL PJ, ZHANG W, MENON MC, et al. Biopsy transcriptome expression profiling to identify kidney transplants at risk of chronic injury: a multicentre, prospective study[J]. Lancet, 2016, 388(10048):983-993. DOI: 10.1016/S0140-6736(16)30826-1.
    [24] YI Z, KEUNG KL, LI L, et al. Key driver genes as potential therapeutic targets in renal allograft rejection[J]. JCI Insight, 2020, 5(15):e136220. DOI: 10.1172/jci.insight.136220.
    [25] NAIR V, JANDOVITZ N, HIRSCH JS, et al. COVID-19 in kidney transplant recipients[J]. Am J Transplant, 2020, 20(7):1819-1825. DOI: 10.1111/ajt.15967.
    [26] KRONBICHLER A, GAUCKLER P, WINDPESSL M, et al. COVID-19: implications for immunosuppression in kidney disease and transplantation[J]. Nat Rev Nephrol, 2020, 16(7):365-367. DOI: 10.1038/s41581-020-0305-6.
    [27] ABRISHAMI A, SAMAVAT S, BEHNAM B, et al. Clinical course, imaging features, and outcomes of COVID-19 in kidney transplant recipients[J]. Eur Urol, 2020, 78(2):281-286. DOI: 10.1016/j.eururo.2020.04.064.
    [28] FAGUER S, DEL BELLO A, ABRAVANEL F, et al. Tocilizumab for hemophagocytic syndrome in a kidney transplant recipient with COVID-19[J]. Ann Intern Med, 2020, 173(6):501-503. DOI: 10.7326/L20-0419.
    [29] SOLIS M, VELAY A, PORCHER R, et al. Neutralizing antibody-mediated response and risk of BK virus-associated nephropathy[J]. J Am Soc Nephrol, 2018, 29(1):326-334. DOI: 10.1681/ASN.2017050532.
    [30] SAWINSKI D, GORAL S. BK virus infection: an update on diagnosis and treatment[J]. Nephrol Dial Transplant, 2015, 30(2):209-217. DOI: 10.1093/ndt/gfu023.
    [31] CHEN XT, CHEN WF, LI J, et al. Urine donor-derived cell-free DNA helps discriminate BK polyomavirus-associated nephropathy in kidney transplant recipients with BK polyomavirus infection[J]. Front Immunol, 2020, 11:1763. DOI: 10.3389/fimmu.2020.01763.
    [32] HUANG Y, CHEN XT, YANG SC, et al. Detection of proximal tubule involvement by BK polyomavirus in kidney transplant recipients with urinary sediment double-immunostaining[J]. Front Immunol, 2020, 11:582678. DOI: 10.3389/fimmu.2020.582678.
    [33] DOBERER K, SCHIEMANN M, STRASSL R, et al. Torque teno virus for risk stratification of graft rejection and infection in kidney transplant recipients-a prospective observational trial[J]. Am J Transplant, 2020, 20(8):2081-2090. DOI: 10.1111/ajt.15810.
    [34] FERNÁNDEZ-RUIZ M. Torque teno virus load as a surrogate marker for the net state of immunosuppression: the beneficial side of the virome[J]. Am J Transplant, 2020, 20(8):1963-1964. DOI: 10.1111/ajt.15872.
    [35] SISE ME, GOLDBERG DS, KORT JJ, et al. Multicenter study to transplant hepatitis C-infected kidneys (MYTHIC): an open-label study of combined glecaprevir and pibrentasvir to treat recipients of transplanted kidneys from deceased donors with hepatitis C virus infection[J]. J Am Soc Nephrol, 2020, 31(11):2678-2687. DOI: 10.1681/ASN.2020050686.
    [36] COUSSEMENT J, KAMAR N, MATIGNON M, et al. Antibiotics versus no therapy in kidney transplant recipients with asymptomatic bacteriuria (BiRT): a pragmatic, multicentre, randomized, controlled trial[J]. Clin Microbiol Infect, 2020, DOI: 10.1016/j.cmi.2020.09.005[Epub ahead of print].
  • 加载中
计量
  • 文章访问数:  233
  • HTML全文浏览量:  76
  • PDF下载量:  53
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-12-03
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2021-01-19

目录

    /

    返回文章
    返回